AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

Blend Therapeutics Presents Preclinical Data for Lead Pentarin™ Program, BTP-277, Demonstrating Specific and Potent Tumor Cell Targeting for Small-Cell Lung Cancer

April 21, 2015

First Product from The Pentarin™ Platform, A Novel Class of Miniaturized Biologic Drug Conjugates (mBDCs) Incorporated in Nanoparticles

Data Presented at AACR Annual Meeting

BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015

BIND Therapeutics Presents Data Highlighting Ability of Accurins to Control Biodistribution and Accumulate in Target Tissue at AACR Annual Meeting 2015

April 22, 2015

- Studies from proprietary and collaboration programs show potential of Accurins as best-in-class targeted therapeutics -

- Data demonstrate optimized drug properties including improved therapeutic index, elevated accumulation in targeted tissue at tumor sites and sustained release -

Blend Therapeutics Presents Preclinical Data for Lead Candidate BTP-114 that Demonstrated Superiority to Cisplatin in Tumor Growth Inhibition

Blend Therapeutics Presents Preclinical Data for Lead Candidate BTP-114 that Demonstrated Superiority to Cisplatin in Tumor Growth Inhibition

April 21, 2015

BTP-114 Is a Novel, Personalized Cisplatin Prodrug with IND to be Filed in Q2 2015

Data Presented at AACR Annual Meeting

Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting

Eleven Biotherapeutics Presents Phase 2 Clinical Data on EBI-005 for the Treatment of Allergic Conjunctivitis at ASCRS 2015 Annual Meeting

April 16, 2015

Data Demonstrated Statistically Significant Improvements in Ocular Itching, Ocular Tearing and Nasal Symptoms Associated with Allergic Conjunctivitis

Avedro Expands Patent Portfolio with Licenses from Caltech and IROC Innocross

Avedro Expands Patent Portfolio with Licenses from Caltech and IROC Innocross

April 14, 2015

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announced today that it has significantly expanded its patent portfolio. Avedro obtained an exclusive license to a patent held by the California Institute of Technology in the field of corneal cross-linking using ultraviolet light. This method patent (U.S. Patent No. 8,414,911) covers two key cross-linking applications: accelerated cross-linking and corneal cross-linking used during refractive surgery.

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer

April 13, 2015

Company to Accelerate Development of Cancer Product Pipeline, with Filing of IND for Lead Product Candidate in Q2 2015

Study Published in Future Microbiology Demonstrates Significant Cost and Survival Benefits for T2 Biosystems' T2Candida Panel for Sepsis

Study Published in Future Microbiology Demonstrates Significant Cost and Survival Benefits for T2 Biosystems' T2Candida Panel for Sepsis

April 8, 2015

LEXINGTON, Mass., April 8, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that results from an analysis on the impact of using the company's T2Candida® Panel were published in Future Microbiology.

Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform

Agenus Acquires Celexion Assets and Expands Its Antibody Discovery Platform

April 8, 2015

SECANT® yeast display technology to provide speed and cost advantages

Combination with Agenus’ mammalian Retrocyte DisplayTM technology to result in a uniquely powerful antibody platform

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) an immunology company developing innovative treatments for cancers and other diseases, today announced the acquisition of key antibody assets of Celexion, LLC, a privately held Cambridge, Mass. biotech company.